Serial circulating-tumor DNA analysis with a tumor naïve next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer
Cancer Res., Dec 01 2023, | https://doi.org/10.1158/0008-5472.CAN-23-1429
Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4.